E7107 (E-7107), a semisynthetic pladienolide B derivative, is a first-in-class and potent precursor messenger ribonucleic acid (pre-mRNA) spliceosome inhibitor that targets the Splicing factor 3B subunit 1 (SF3b1) of the spliceosome, and shows significant antitumor activities. It is a semisynthetic derivative of the natural product pladienolide B which was originally isolated from Streptomyces platensis. Development of E7107 was suspended after Phase I clinical trials due to an unacceptable profile of adverse events.

纯度：≥98%

CAS：630100-90-2